Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

Rhea-AI Summary

Sight Sciences (Nasdaq: SGHT), an eyecare technology company specializing in innovative interventional technologies, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.

The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results for the quarter ended March 31, 2025. Investors can access the live webcast and replay (available for 90 days) through the company's website at www.sightsciences.com in the Investors page under News & Events section.

MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com, on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event.

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (“MGD”), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information. 

Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.

© 2025 Sight Sciences. All rights reserved.

Media contact:
pr@sightsciences.com

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
investor.relations@sightsciences.com

FAQ

When will Sight Sciences (SGHT) release Q1 2025 earnings?

Sight Sciences will release Q1 2025 earnings on May 8, 2025, after market close.

How can investors access Sight Sciences' Q1 2025 earnings call?

Investors can access the live webcast at www.sightsciences.com on the Investors page in the News & Events section.

What time is Sight Sciences' (SGHT) Q1 2025 earnings call?

The earnings call is scheduled for 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 8, 2025.

How long will Sight Sciences' Q1 2025 earnings webcast be available for replay?

The earnings webcast will be available for replay for at least 90 days after the event.